Top

Endocrine

Published in:

01-05-2018 | Meta-Analysis

Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials

Authors: Huijin Wu, Hua Shang, Jing Wu

Published in: Endocrine | Issue 2/2018

Abstract

Purpose

Given the increased risk of incident diabetes and the side effects on glycemic control with statin treatment, statin and ezetimibe combination therapy has been widely used. However, whether the same concern exists in ezetimibe remains uncertain. This meta-analysis aimed to investigate the influence of ezetimibe treatment on glycemic control.

Methods

Articles were searched from PubMed, EMBASE, and Cochrane Library. Randomized controlled trials (RCTs) were included if they compared the effects of ezetimibe with placebo, ezetimibe plus statin with the same statin, or low-dose stain plus ezetimibe with high-dose statin on FBG and glycosylated hemoglobin A1c (HbA1c).

Results

Of the 2440 articles retrieved, 16 RCTs were included. Ezetimibe did not cause side effects on FBG (WMD −0.62, 95% CI: −3.13 to 1.90) and HbA1c (WMD 0.07, 95% CI: −0.07 to 0.20%). No significant changes in FBG (WMD −1.78, 95% CI: −6.33 to 2.77%) and HbA1c (WMD −0.05, 95% CI: −0.14 to 0.05%) were observed in ezetimibe plus low-dose statin treatment compared with high-dose statin. According to subgroup analysis, in comparison with high-dose statin, ezetimibe plus low-dose statin taken for more than 3 months showed a significant decrease in FBG (WMD −7.12, 95% CI: −13.86 to −0.38%) compared with that taken for less than 3 months (WMD 0.90, 95% CI: −2.91 to 4.71%). Nevertheless, this difference was invalid when the study conducted by Dagli et al. was removed.

Conclusions

Compared with high-dose statin therapy, ezetimibe with low-dose statin for more than 3 months may have a beneficial tendency of effects on glycemic control.

C.J. Murray, A.D. Lopez, Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349(9061), 1269–1276 (1997). https://doi.org/10.1016/S0140-6736(96)07493-4 CrossRefPubMed

C. Baigent, A. Keech, P.M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, R. Simes; Cholesterol Treatment, C. Trialists, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267–1278 (2005). https://doi.org/10.1016/S0140-6736(05)67394-1 CrossRefPubMed

Cholesterol Treatment Trialists, C., P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, R. Peto, J. Armitage, C. Baigent, Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371(9607), 117–125 (2008). https://doi.org/10.1016/S0140-6736(08)60104-X CrossRef

N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735–742 (2010). https://doi.org/10.1016/S0140-6736(09)61965-6 CrossRefPubMed

S. Erqou, C.C. Lee, A.I. Adler, Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia 57(12), 2444–2452 (2014). https://doi.org/10.1007/s00125-014-3374-x CrossRefPubMed

E.A. Nutescu, N.L. Shapiro, Ezetimibe: a selective cholesterol absorption inhibitor. Pharmacotherapy 23(11), 1463–1474 (2003)CrossRefPubMed

M. Garcia-Calvo, J. Lisnock, H.G. Bull, B.E. Hawes, D.A. Burnett, M.P. Braun, J.H. Crona, H.R. Davis Jr., D.C. Dean, P.A. Detmers, M.P. Graziano, M. Hughes, D.E. Macintyre, A. Ogawa, A. O’Neill K., S.P. Iyer, D.E. Shevell, M.M. Smith, Y.S. Tang, A.M. Makarewicz, F. Ujjainwalla, S.W. Altmann, K.T. Chapman, N.A. Thornberry, The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl Acad. Sci. USA 102(23), 8132–8137 (2005). https://doi.org/10.1073/pnas.0500269102 CrossRefPubMedPubMedCentral

M. Deushi, M. Nomura, A. Kawakami, M. Haraguchi, M. Ito, M. Okazaki, H. Ishii, M. Yoshida, Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 581(29), 5664–5670 (2007). https://doi.org/10.1016/j.febslet.2007.11.023 CrossRefPubMed

T. Muraoka, K. Aoki, T. Iwasaki, K. Shinoda, A. Nakamura, H. Aburatani, S. Mori, K. Tokuyama, N. Kubota, T. Kadowaki, Y. Terauchi, Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 60(5), 617–628 (2011). https://doi.org/10.1016/j.metabol.2010.06.008 CrossRefPubMed

10.

Y. Nozaki, K. Fujita, M. Yoneda, K. Wada, Y. Shinohara, H. Takahashi, H. Kirikoshi, M. Inamori, K. Kubota, S. Saito, T. Mizoue, N. Masaki, Y. Nagashima, Y. Terauchi, A. Nakajima, Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J. Hepatol. 51(3), 548–556 (2009). https://doi.org/10.1016/j.jhep.2009.05.017 CrossRefPubMed

11.

S. Hiramitsu, Y. Ishiguro, H. Matsuyama, K. Yamada, K. Kato, M. Noba, A. Uemura, S. Yoshida, Y. Matsubara, A. Kani, K. Hasegawa, H. Hishida, Y. Ozaki, The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. J. Atheroscler. Thromb. 17(1), 106–114 (2010)CrossRefPubMed

12.

S. Yagi, M. Akaike, K. Aihara, T. Iwase, K. Ishikawa, S. Yoshida, Y. Sumitomo-Ueda, K. Kusunose, T. Niki, K. Yamaguchi, K. Koshiba, Y. Hirata, M. Dagvasumberel, Y. Taketani, N. Tomita, H. Yamada, T. Soeki, T. Wakatsuki, T. Matsumoto, M. Sata, Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J. Atheroscler. Thromb. 17(2), 173–180 (2010)CrossRefPubMed

13.

N. Dagli, M. Yavuzkir, I. Karaca, The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 30(6), 230–235 (2007). https://doi.org/10.1007/s10753-007-9041-3 CrossRefPubMed

14.

N. Tamaki, H. Ueno, Y. Morinaga, T. Shiiya, M. Nakazato, Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J. Atheroscler. Thromb. 19(6), 532–538 (2012)CrossRefPubMed

15.

Y. Takeshita, T. Takamura, M. Honda, Y. Kita, Y. Zen, K. Kato, H. Misu, T. Ota, M. Nakamura, K. Yamada, H. Sunagozaka, K. Arai, T. Yamashita, E. Mizukoshi, S. Kaneko, The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 57(5), 878–890 (2014). https://doi.org/10.1007/s00125-013-3149-9 CrossRefPubMed

16.

E. Moutzouri, E. Liberopoulos, D.P. Mikhailidis, M.S. Kostapanos, A.A. Kei, H. Milionis, M. Elisaf, Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int. J. Clin. Pract. 65(11), 1141–1148 (2011). https://doi.org/10.1111/j.1742-1241.2011.02779.x CrossRefPubMed

17.

K. Kikuchi, U. Nezu, K. Inazumi, T. Miyazaki, K. Ono, K. Orime, J. Shirakawa, K. Sato, H. Koike, T. Wakasugi, M. Sato, C. Kawakami, S. Watanabe, T. Yamakawa, Y. Terauchi, Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J. Atheroscler. Thromb. 19(12), 1093–1101 (2012)CrossRefPubMed

18.

M. Gonzalez-Ortiz, E. Martinez-Abundis, A.M. Kam-Ramos, E. Hernandez-Salazar, M.G. Ramos-Zavala, Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc. Drugs Ther. 20(2), 143–146 (2006). https://doi.org/10.1007/s10557-006-7805-x CrossRefPubMed

19.

M. Kishimoto, T. Sugiyama, K. Osame, D. Takarabe, M. Okamoto, M. Noda, Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes. J. Med. Invest. 58(1-2), 86–94 (2011)CrossRefPubMed

20.

R. Cai, Y. Yuan, J. Sun, W. Xia, R. Huang, S. Tian, X. Dong, Y. Shen, S. Wang, Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. Expert. Opin. Pharmacother. 17(14), 1839–1849 (2016). https://doi.org/10.1080/14656566.2016.1220539 CrossRefPubMed

21.

J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A. Sterne, G. Cochrane Bias Methods, Cochrane Statistical Methods, G.: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011). https://doi.org/10.1136/bmj.d5928 CrossRefPubMedPubMedCentral

22.

J.P. Higgins, S. Green, Cochrane handbook for systematic reviews of interventions version 5.1.0. http://handbook.cochrane.org/

23.

K. Torimoto, Y. Okada, H. Mori, M. Hajime, K. Tanaka, A. Kurozumi, M. Narisawa, S. Yamamoto, T. Arao, H. Matsuoka, N. Inokuchi, Y. Tanaka, Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids Health Dis. 12, 137 (2013). https://doi.org/10.1186/1476-511X-12-137 CrossRefPubMedPubMedCentral

24.

I. Saito, K. Azuma, T. Kakikawa, N. Oshima, M.E. Hanson, A.M. Tershakovec, A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. Lipids Health Dis. 14, 40 (2015). https://doi.org/10.1186/s12944-015-0036-z CrossRefPubMedPubMedCentral

25.

D.C. Chan, G.F. Watts, S.K. Gan, E.M. Ooi, P.H. Barrett, Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33(5), 1134–1139 (2010). https://doi.org/10.2337/dc09-1765 CrossRefPubMedPubMedCentral

26.

K.J. Kim, S.H. Kim, Y.W. Yoon, S.W. Rha, S.J. Hong, C.H. Kwak, W. Kim, C.W. Nam, M.Y. Rhee, T.H. Park, T.J. Hong, S. Park, Y. Ahn, N. Lee, H.K. Jeon, D.W. Jeon, K.R. Han, K.W. Moon, I.H. Chae, H.S. Kim, Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc. Ther. 34(5), 371–382 (2016). https://doi.org/10.1111/1755-5922.12213 CrossRefPubMedPubMedCentral

27.

K. Winkler, S. Jacob, T. Muller-Schewe, M.M. Hoffmann, T. Konrad, Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 220(1), 189–193 (2012). https://doi.org/10.1016/j.atherosclerosis.2011.10.043 CrossRefPubMed

28.

P. Ruggenenti, D. Cattaneo, S. Rota, I. Iliev, A. Parvanova, O. Diadei, B. Ene-Iordache, S. Ferrari, A.C. Bossi, R. Trevisan, A. Belviso, G. Remuzzi, Ezetimibe, Simvastatin in Dyslipidemia of Diabetes Study, G.: Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 33(9), 1954–1956 (2010). https://doi.org/10.2337/dc10-0320 CrossRefPubMedPubMedCentral

29.

R. Krysiak, W. Zmuda, B. Okopien, The effect of simvastatin-ezetimibe combination therapy on adipose tissue hormones and systemic inflammation in patients with isolated hypercholesterolemia. Cardiovasc. Ther. 32(2), 40–46 (2014). https://doi.org/10.1111/1755-5922.12057 CrossRefPubMed

30.

G. Villegas-Rivera, L.M. Roman-Pintos, E.G. Cardona-Munoz, O. Arias-Carvajal, A.D. Rodriguez-Carrizalez, R. Troyo-Sanroman, F.P. Pacheco-Moises, A. Moreno-Ulloa, A.G. Miranda-Diaz, Effects of ezetimibe/simvastatin and rosuvastatin on oxidative stress in diabetic neuropathy: a randomized, double-blind, placebo-controlled clinical trial. Oxid. Med Cell Longev. 2015, 756294 (2015). https://doi.org/10.1155/2015/756294 CrossRefPubMedPubMedCentral

31.

S.C. Ramos, F.A. Fonseca, S.H. Kasmas, F.T. Moreira, T. Helfenstein, N.C. Borges, R.A. Moreno, V.M. Rezende, F.C. Silva, M.C. Izar, The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. Nutr. J. 10, 80 (2011). https://doi.org/10.1186/1475-2891-10-80 CrossRefPubMedPubMedCentral

32.

Y. Kawagoe, Y. Hattori, A. Nakano, C. Aoki, S. Tanaka, S. Ohta, T. Iijima, A. Tomizawa, T. Jojima, H. Kase, K. Kasai, Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr. J. 58(3), 171–175 (2011)CrossRefPubMed

33.

K. Sakamoto, M. Kawamura, T. Kohro, M. Omura, T. Watanabe, K. Ashidate, T. Horiuchi, H. Hara, N. Sekine, R. Chin, M. Tsujino, T. Hiyoshi, M. Tagami, A. Tanaka, Y. Mori, T. Inazawa, T. Hirano, T. Yamazaki, T. Shiba, R.S. Group, Effect of ezetimibe on LDL-C lowering and atherogenic lipoprotein profiles in type 2 diabetic patients poorly controlled by statins. PLoS ONE 10(9), e0138332 (2015). https://doi.org/10.1371/journal.pone.0138332 CrossRefPubMedPubMedCentral

34.

W.L. Baker, R. Talati, C.M. White, C.I. Coleman, Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res. Clin. Pract. 87(1), 98–107 (2010). https://doi.org/10.1016/j.diabres.2009.10.008 CrossRefPubMed

35.

S. Hiramitsu, K. Miyagishima, J. Ishii, S. Matsui, H. Naruse, K. Shiino, F. Kitagawa, Y. Ozaki, Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J. Cardiol. 60(5), 395–400 (2012). https://doi.org/10.1016/j.jjcc.2012.07.010 CrossRefPubMed

36.

S. Ichimori, S. Shimoda, R. Goto, Y. Matsuo, T. Maeda, N. Furukawa, J. Kawashima, S. Kodama, T. Sekigami, S. Isami, K. Nishida, E. Araki, Ezetimibe improves glucose metabolism by ameliorating hepatic function in Japanese patients with type 2 diabetes. J. Diabetes Investig. 3(2), 179–184 (2012). https://doi.org/10.1111/j.2040-1124.2011.00147.x CrossRefPubMed

37.

L. Bozzetto, G. Annuzzi, G.D. Corte, L. Patti, P. Cipriano, A. Mangione, G. Riccardi, A.A. Rivellese, Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 217(1), 142–148 (2011). https://doi.org/10.1016/j.atherosclerosis.2011.03.012 CrossRefPubMed

38.

T. Tsunoda, T. Nozue, M. Yamada, I. Mizuguchi, M. Sasaki, I. Michishita, Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res. Clin. Pract. 100(1), 46–52 (2013). https://doi.org/10.1016/j.diabres.2012.12.026 CrossRefPubMed

39.

A.Y. Her, J.Y. Kim, S.M. Kang, D. Choi, Y. Jang, N. Chung, I. Manabe, S.H. Lee, Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J. Cardiovasc. Pharmacol. Ther. 15(2), 167–174 (2010). https://doi.org/10.1177/1074248409357922 CrossRefPubMed

40.

A.L. Kater, M.C. Batista, S.R. Ferreira, Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 59(6), 921–926 (2010). https://doi.org/10.1016/j.metabol.2010.02.011 CrossRefPubMed

41.

Y. Zhong, J. Wang, P. Gu, J. Shao, B. Lu, S. Jiang, Effect of ezetimibe on insulin secretion in db/db diabetic mice. Exp. Diabetes Res. 2012((), 420854 (2012). https://doi.org/10.1155/2012/420854 PubMedPubMedCentral

42.

T. Nakamura, M. Hirano, Y. Kitta, D. Fujioka, Y. Saito, K. Kawabata, J.E. Obata, Y. Watanabe, K. Watanabe, K. Kugiyama, A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J. Cardiol. 60(1), 12–17 (2012). https://doi.org/10.1016/j.jjcc.2012.02.005 CrossRefPubMed

43.

J.C. Sandoval, Y. Nakagawa-Toyama, D. Masuda, Y. Tochino, H. Nakaoka, R. Kawase, M. Yuasa-Kawase, K. Nakatani, M. Inagaki, K. Tsubakio-Yamamoto, T. Ohama, A. Matsuyama, M. Nishida, M. Ishigami, I. Komuro, S. Yamashita, Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J. Atheroscler. Thromb. 17(9), 914–924 (2010)CrossRefPubMed

44.

D. Masuda, Y. Nakagawa-Toyama, K. Nakatani, M. Inagaki, K. Tsubakio-Yamamoto, J.C. Sandoval, T. Ohama, M. Nishida, M. Ishigami, S. Yamashita, Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur. J. Clin. Invest. 39(8), 689–698 (2009). https://doi.org/10.1111/j.1365-2362.2009.02163.x CrossRefPubMed

45.

G. Boden, M. Laakso, Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 27(9), 2253–2259 (2004)CrossRefPubMed

46.

M. Bajaj, S. Suraamornkul, S. Kashyap, K. Cusi, L. Mandarino, R.A. DeFronzo, Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J. Clin. Endocrinol. Metab. 89(9), 4649–4655 (2004). https://doi.org/10.1210/jc.2004-0224 CrossRefPubMed

47.

M. Nomura, H. Ishii, A. Kawakami, M. Yoshida, Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance. Am. J. Physiol. Endocrinol. Metab. 297(5), E1030–E1038 (2009). https://doi.org/10.1152/ajpendo.00343.2009 CrossRefPubMed

Title: Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials
Authors: Huijin Wu
Hua Shang
Jing Wu
Publication date: 01-05-2018
Publisher: Springer US
Published in: Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1541-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients

Type 2 diabetes and cardiovascular prevention: the dogmas disputed

IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea

PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line

Oro-dental pathologies in acromegaly

Shear wave elastography in the diagnostics of parathyroid adenomas–new application of the method

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page